James Crowe
Faculty Member
Last active: 3/31/2019

  1. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE (2016) Cell 164(3): 392-405
    › Primary publication · 26806128 (PubMed) · PMC4733404 (PubMed Central)
  2. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE (2016) Cell 167(3): 684-694.e9
    › Primary publication · 27768891 (PubMed) · PMC5093772 (PubMed Central)
  3. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE, Bukreyev A (2016) J Virol 90(8): 3890-3901
    › Primary publication · 26819310 (PubMed) · PMC4810552 (PubMed Central)
  4. Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells. Clark KB, Hsiao HM, Bassit L, Crowe JE, Schinazi RF, Perng GC, Villinger F (2016) Virology : 162-72
    › Primary publication · 27058763 (PubMed) · PMC5538722 (PubMed Central)
  5. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Aman MJ, Dye JM, Lai JR, Chandran K (2016) Science 354(6310): 350-354
    › Primary publication · 27608667 (PubMed) · PMC5647781 (PubMed Central)
  6. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. Wen X, Pickens J, Mousa JJ, Leser GP, Lamb RA, Crowe JE, Jardetzky TS (2016) PLoS One 11(5): e0155917
    › Primary publication · 27224013 (PubMed) · PMC4880302 (PubMed Central)
  7. Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe JE, Spiller BW (2015) Proc Natl Acad Sci U S A 112(30): 9346-51
    › Primary publication · 26170302 (PubMed) · PMC4522792 (PubMed Central)
  8. Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies. Smith SA, Crowe JE (2015) Microbiol Spectr 3(1): AID-0027-2014
    › Primary publication · 26104564 (PubMed)
  9. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO (2015) Cell 160(5): 904-912
    › Primary publication · 25723165 (PubMed) · PMC4344967 (PubMed Central)
  10. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. Callaway JB, Smith SA, McKinnon KP, de Silva AM, Crowe JE, Ting JP (2015) J Biol Chem 290(28): 17306-20
    › Primary publication · 26032420 (PubMed) · PMC4498069 (PubMed Central)